Szaflarski JP, et al. - For this investigation, 25 US-based expanded-access program (EAP) sites enrolling patients with treatment-resistant epilepsy (TRE) taking stable doses of antiepileptic drugs at baseline were incorporated to identify long-term safety and treatment effects of cannabidiol (CBD) in children and adults with TREs. Add-on CBD reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks. The proportion of patients with ≥ 50%, ≥ 75%, and 100% reductions in convulsive seizures were 52%, 31%, and 11%, respectively, at 12 weeks. Similar rates for both of these findings were seen through 96 weeks. Findings from the present study suggested that add-on CBD could be an efficacious long-term treatment option for TRE. It was observed that CBD was generally well tolerated; diarrhea and somnolence were the most common adverse events.